Regulatory FDA points to liver injury with Amgen’s Tavneos PharmaphorumThe FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.RegulatoryImmunology & InflammationRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug. RegulatoryImmunology & InflammationRead full story Post navigation Previous: Eli Lilly outlays $7.8bn to acquire sleep drug biotech CentessaNext: Telomir seeks FDA approval for Telomir-1 to treat breast cancer Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
